Delivery Order SPE2DR25D3202-SPE2DR26F8E2G
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Tamsulosin HCL 0.4 mg capsules (1,000 units) with a contract value of $1,445.62. This is a firm fixed-price delivery order with an ultimate completion date of December 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, with a contract ceiling value of $1,727.65. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by August 8, 2025. The award represents a routine pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg at a firm fixed price of $1,060.05. The order will be completed by December 12, 2025, and performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This is a non-set-aside award issued under competitive procedures, reflecting the contractor's established capability to meet federal pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of Tamsulosin HCL 0.4 mg capsules (1,000 units) valued at $1,860.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. The contract is valued at $7,754.47 with a firm fixed price structure and an ultimate completion date of December 11, 2025. This delivery order is classified as a non-set-aside award, meaning it was competitively awarded without restrictions. Performance will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, with a contract value of $1,192.79 and a completion date of September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical will be supplied from the vendor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 20, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg at a firm fixed price of $1,788.69. This non-competitive, non-set-aside delivery order is scheduled for completion by May 21, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply requirements. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $2,702.16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a common medication used to treat benign prostatic hyperplasia. This firm fixed-price delivery order, valued at $11,771.03, is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive procedures with no...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, with a ceiling value of $4,156.80 and a firm fixed price structure. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of December 9, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical...
- SPE2DR25D3202Indefinite Delivery Contract
- SPE2DR25D3202-SPE2DR26F8E2GDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 24, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules at a firm fixed price of $1,339.94. This non-competitive, non-set-aside delivery order is scheduled for completion by December 26, 2025, with performance to be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award represents a small-value pharmaceutical transaction typical of routine medical supply replenishment orders processed through the Defense Logistics Agency's medical supply chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive prime vendor agreement valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying branded and generic medications, vaccines, and medical supplies to support military healthcare systems and the Defense Health Agency. The company's extensive portfolio of federal awards demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains through open competition and firm fixed-price delivery mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 12/23/25 |